JCP Editors

According to a recent study published in JAMA Dermatology, which of the following factors do NOT contribute to treatment delay in melanoma?
A recent report suggests that there is a steady increase in costs of FDA approved anticancer drugs over time, regardless of competition or supplemental indications.
A recent study compared the safety and efficacy of multiple chemotherapy agents in treating advanced liposarcoma.
A recent study compared the effectiveness of stereotactic ablative body radiotherapy with conventional full fractionated radiotherapy in prolonging time to local failure in patients with inoperable stage I non-small cell lung cancer.
JCP staff were on hand to cover the meeting and engage with stakeholders throughout the weekend. We encourage all who are able to attend next year’s CPC, which will be held October 26-28, 2018, in Boston, MA.
Journal of Clinical Pathways spoke with Dr Miller about a recent blog post, and how he sees future payment models adapting to an influx of costly new therapies as they enter the marker.
Journal of Clinical Pathways spoke with Editorial Advisory Board member Ayman Elfiky, MD, MSc, MPH, about how clinical pathways are used at Dana-Farber Cancer Institute (Boston, MA).
A recent study suggests that improvements in Hodgkin lymphoma treatment—including smaller radiation fields—have led to higher cure rates and lower rates of toxicity.
Patients with a certain B-cell malignancy and abnormal liver function tests at diagnosis are at risk of shorter overall survival compared with those who have normal liver function.
A recent study assessed the hypothesis that prolonging the platinum-free interval with platinum-free chemotherapy may offer improved outcomes in patients with progressing ovarian cancer.